| dc.contributor.author |
Gaikwad, Anil Bhanudas |
|
| dc.date.accessioned |
2023-12-27T06:56:44Z |
|
| dc.date.available |
2023-12-27T06:56:44Z |
|
| dc.date.issued |
2023-11 |
|
| dc.identifier.uri |
https://www.sciencedirect.com/science/article/pii/S0024320523007300 |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/xmlui/handle/123456789/13528 |
|
| dc.description.abstract |
Targeting Toll-like receptor 4 (TLR4) and Angiotensin II type 1 receptor (AT1R) could provide renoprotection during acute kidney injury (AKI) mainly by regulating inflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. Phloretin (TLR4 inhibitor) as an add-on therapy to losartan (AT1R inhibitor) could provide more therapeutic benefits against AKI under diabetic condition. We aimed to study the effect of phloretin as an add-on therapy to losartan against AKI under diabetic condition. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.subject |
Pharmacy |
en_US |
| dc.subject |
Inflammation |
en_US |
| dc.subject |
Phloretin |
en_US |
| dc.subject |
Toll-like receptor-4 (TLR4) |
en_US |
| dc.subject |
Diabetes |
en_US |
| dc.subject |
Acute Kidney Injury (AKI) |
en_US |
| dc.title |
Phloretin as an add-on therapy to losartan attenuates diabetes-induced AKI in rats: A potential therapeutic approach targeting TLR4-induced inflammation |
en_US |
| dc.type |
Article |
en_US |